Long-Term Safety and Low Relapse Rate Observed in Phase 3 ADVANCE-CIDP 3 Trial of Hyqvia

Published Date: 23 Jun 2024

A phase 3 trial showed that over time, Hyqvia is a safe and well-tolerated maintenance treatment for patients with chronic inflammatory demyelinating polyneuropathy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia

2.

Glioblastoma treatment breakthrough shows promise

3.

A computer-aided diagnostic system for improved detection of breast cancer.

4.

Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy

5.

Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot